Associations between androgen and vitamin D receptor microsatellites and postmenopausal breast cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 9, 2007, Pages 1775-1783

  Wedrén, Sara ^a   Magnusson, Cecilia ^a   Humphreys, Keith ^a   Melhus, Håkan ^b   Kindmark, Andreas ^b   Stiger, Fredrik ^b   Branting, Maria ^b   Persson, Ingemar ^a,c   Baron, John ^d   Weiderpass, Elisabete ^a,e,f  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

^e Cancer Registry of Norway ^*  (Norway)

^f FOLKHÄLSAN RESEARCH CENTER   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; POLYADENYLIC ACID; VITAMIN D RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MICROSATELLITE MARKER; POSTMENOPAUSE; PRIORITY JOURNAL;

AGED; ALLELES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICROSATELLITE REPEATS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; RECEPTORS, ANDROGEN; RECEPTORS, CALCITRIOL; RISK; RISK FACTORS; SWEDEN;

EID: 34548843339     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-1096     Document Type: Article

References (65)

1. Ferro P, Catalano M, Dell'Eva R, Fortunati N, Pfeffer U. The androgen receptor CAG repeat: a modifier of carcinogenesis? Mol Cell Endocrinol 2002;193:109.
2. Ortmann J, Prifti S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T, Rabe T. Testosterone and 5α-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecol Endocrinol 2002;16:113-20.
3. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
4. Knoke I, Allera A, Wieacker P. Significance of the CAG repeat length in the androgen receptor gene (AR) for the transactivation function of an M780I mutant AR. Hum Genet 1999;104:257-61.
5. Beilin J, Ball EM, Favaloro JM, Zajac JD. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J Mol Endocrinol 2000;25:85-96.
6. Irvine RA, Ma H, Yu MC, Ross RK, Stallcup MR, Coetzee GA. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum Mol Genet 2000;9:267-74.
7. Mononen N, Ikonen T, Autio V, et al. Androgen receptor CAG polymorphism and prostate cancer risk. Hum Genet 2002;111:166-71.
8. Hsing AW, Chokkalingam AP, Gao YT, et al. Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2002;11:337-41.
9. Ekman P, Gronberg H, Matsuyama H, Kivineva M, Bergerheim US, Li C. Links between genetic and environmental factors and prostate cancer risk. Prostate 1999;39:262-8.
10. Andersson P, Varenhorst E, Soderkvist P. Androgen receptor and vitamin D receptor gene polymorphisms and prostate cancer risk. Eur J Cancer 2006;42:2833-7.
11. Eckardstein SV, Schmidt A, Kamischke A, Simoni M, Gromoll J, Nieschlag E. CAG repeat length in the androgen receptor gene and gonadotrophin suppression influence the effectiveness of hormonal male contraception. Clin Endocrinol (Oxf) 2002;57:647-55.
12. Kukuvitis A, Georgiou I, Bouba I. Association of oestrogen receptor a polymorphisms and androgen receptor CAG trinucleotide repeats with male infertility: a study in 109 Greek infertile men. Int J Androl 2002;25:149-52.
13. Dowsing AT, Yong EL, Clark M, McLachlan RI, de Kretser DM, Trounson AO. Linkage between male infertility and trinucleotide repeat expansion in the androgen-receptor gene. Lancet 1999;354:640-3.
14. Giguère Y, Dewailly E, Brisson J, et al. Short polyglutamine tracts in the androgen receptor are protective against breast cancer in the general population. Cancer Res 2001;61:5869-74.
15. Liede A, Zhang W, De Leon Matsuda ML, Tan A, Narod SA. Androgen receptor gene polymorphism and breast cancer susceptibility in the Philippines. Cancer Epidemiol Biomarkers Prev 2003;12:848-52.
16. Elhaji YA, Gottlieb B, Lumbroso R, et al. The polymorphic CAG repeat of the androgen receptor gene: a potential role in breast cancer in women over 40. Breast Cancer Res Treat 2001;70:109-16.
17. Haiman CA, Brown M, Hankinson SE, et al. The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses Health Study. Cancer Res 2002;62:1045-9.
18. Suter NM, Malone KE, Daling JR, Doody DR, Ostrander EA. Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women. Cancer Epidemiol Biomarkers Prev 2003;12:127-35.
19. Cox DG, Blanche H, Pearce CL, et al. A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Breast Cancer Res 2006;8:R54.
20. Dunning AM, McBride S, Gregory J, et al. No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. Carcinogenesis 1999;20:2131-5.
21. Spurdle AB, Dite GS, Chen X, et al. Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years. J Natl Cancer Inst 1999;91:961-6.
22. Yu H, Bharaj B, Vassilikos EJ, Giai M, Diamandis EP. Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. Breast Cancer Res Treat 2000;59:153-61.
23. Iobagiu C, Lambert C, Normand M, Genin C. Microsatellite profile in hormonal receptor genes associated with breast cancer. Breast Cancer Res Treat 2006;95:153-9.
24. Escaleira MT, Sonohara S, Brentani MM. Sex steroids induced upregulation of 1,25-(OH)2 vitamin D3 receptors in T 47D breast cancer cells. J Steroid Biochem Mol Biol 1993;45:257-63.
25. Zhao XY, Peehl DM, Navone NM, Feldman D. 1α,25-Dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgendependent and androgen-independent mechanisms. Endocrinology 2000;141:2548-56.
26. Yamagata M, Nakajima S, Tokita A, et al. Analysis of the stable levels of messenger RNA derived from different polymorphic alleles in the vitamin D receptor gene. J Bone Miner Metab 1999;17:164-70.
27. Durrin LK, Haile RW, Ingles SA, Coetzee GA. Vitamin D receptor 3′-untranslated region polymorphisms: lack of effect on mRNA stability. Biochim Biophys Acta 1999;1453:311-20.
28. Morrison NA, Qi JC, Tokita A, et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994;367:284-7.
29. Ingles SA, Ross RK, Yu MC, et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89:166-70.
30. Correa-Cerro L, Berthon P, Haussler J, et al. Vitamin D receptor polymorphisms as markers in prostate cancer. Hum Genet 1999;105:281-7.
31. Veronique-Baudin J, Dieye M, Kouyoumdjian JC, Vacheron F, Draganescu C, Azaloux H. [Case-control study of the genes of receptors of the androgens of vitamin-D and of 5-areductase in a population of Afro-Caribbean population with prostate cancer]. Prog Urol 2006;16:303-10.
32. Giguère Y, Dodin S, Blanche C, Morgan K, Rousseau F. The association between heel ultrasound and hormone replacement therapy is modulated by a two-locus vitamin D and estrogen receptor genotype. J Bone Miner Res 2000;15:1076-84.
33. Feskanich D, Hunter DJ, Willett WC, et al. Vitamin D receptor genotype and the risk of bone fractures in women. Epidemiology 1998;9:535-9.
34. Sainz J, Van Tornout JM, Loro ML, Sayre J, Roe TF, Gilsanz V. Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent. N Engl J Med 1997;337:77-82.
35. Hou MF, Tien YC, Lin GT, et al. Association of vitamin D receptor gene polymorphism with sporadic breast cancer in Taiwanese patients. Breast Cancer Res Treat 2002;74:1-7.
36. Bretherton-Watt D, Given-Wilson R, Mansi JL, Thomas V, Carter N, Colston KW. Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population. Br J Cancer 2001;85:171-5.
37. Ingles SA, Garcia DG, Wang W, et al. Vitamin D receptor genotype and breast cancer in Latinas (United States). Cancer Causes Control 2000;11:25-30.
38. Curran JE, Vaughan T, Lea RA. Association of A vitamin D receptor polymorphism with sporadic breast cancer development. Int J Cancer 1999;83:723-6.
39. Sillanpää P, Hirvonen A, Kataja V, et al. Vitamin D receptor gene polymorphism as an important modifier of positive family history related breast cancer risk. Pharmacogenetics 2004;14:239-45.
40. Guy M, Lowe LC, Bretherton-Watt D, et al. Vitamin D receptor gene polymorphisms and breast cancer risk. Clin Cancer Res 2004;10:5472-81.
41. Newcomb PA, Kim H, Trentham-Dietz A, Farin F, Hunter D, Egan KM. Vitamin D receptor polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1503-4.
42. Lundin AC, Soderkvist P, Eriksson B, Bergman-Jungestrom M, Wingren S; South-East Sweden Breast Cancer Group. Association of breast cancer progression with a vitamin D receptor gene polymorphism. Cancer Res 1999;59:2332-4.
43. Ruggiero M, Pacini S, Aterini S, Fallai C, Ruggiero C, Pacini P. Vitamin D receptor gene polymorphism is associated with metastatic breast cancer. Oncol Res 1998;10:43-6.
44. Buyru N, Tezol A, Yosunkaya-Fenerci E, Dalay N. Vitamin D receptor gene polymorphisms in breast cancer. Exp Mol Med 2003;35:550-5.
45. Magnusson C, Baron J, Persson I, et al. Body size in different periods of life and breast cancer risk in post-menopausal women. Int J Cancer 1998;76:29-34.
46. Magnusson C, Colditz G, Rosner B, Bergstrom R, Persson I. Association of family history and other risk factors with breast cancer risk (Sweden). Cancer Causes Control 1998;9:259-67.
47. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogenprogestin- replacement therapy. Int J Cancer 1999;81:339-44.
48. Magnusson CM, Persson IR, Baron JA, Ekbom A, Bergstrom R. Adami HO. The role of reproductive factors and use of oral contraceptives in the aetiology of breast cancer in women aged 50 to 74 years. Int J Cancer 1999;80:231-6.
49. Rylander-Rudqvist T, Wedren S, Jonasdó ttir G, et al. Cytochrome P450 1B1 gene polymorphisms and postmenopausal endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 2004;13:1515-20.
50. Isola J, DeVries S, Chu L, Ghazvini S, Waldman F. Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol 1994;145:1301-8.
51. Raymond M, Rousset F. Genepop (version 1.2): population genetics software for exact tests and ecumenicism. J Hered 1995;86:248-9. Available from: http://genepop.curtin.edu.au/.
52. Aspinall SR, Stamp S, Davison A, Shenton BK, Lennard TW. The proliferative effects of 5-androstene-3β, 17β-diol, and 5α-dihydrotestosterone on cell cycle analysis and cell proliferation in MCF7, T47D, and MDAMB231 breast cancer cell lines. J Steroid Biochem Mol Biol 2004;88:37-51.
53. Somboonporn W, Davis SR. Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev 2004;25:374-88.
54. Comings DE, Muhleman D, Johnson JP, MacMurray JP. Parentdaughter transmission of the androgen receptor gene as an explanation of the effect of father absence on age of menarche. Child Dev 2002;73:1046-51.
55. Westberg L, Baghaei F, Rosmond R, et al. Polymorphisms of the androgen receptor gene and the estrogen receptor β gene are associated with androgen levels in women. J Clin Endocrinol Metab 2001;86:2562-8.
56. MacLean HE, Brown RW, Beilin J, Warne GL, Zajac JD. Increased frequency of long androgen receptor CAG repeats in male breast cancers. Breast Cancer Res Treat 2004;88:239-46.
57. Rebbeck TR, Kantoff PW, Krithivas K, et al. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet 1999;64:1371-7.
58. Dagan E, Friedman E, Paperna T, Carmi N, Gershoni-Baruch R. Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype. Eur J Hum Genet 2002;10:724-8.
59. Spurdle AB, Antoniou AC, Duffy DL, et al. The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2005;7:R176-83.
60. Kadouri L, Easton DF, Edwards S, et al. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer 2001;85:36-40.
61. Given HF, Radbourne R, Oag H, et al. The androgen receptor exon 1 trinucleotide repeat does not act as a modifier of the age of presentation in breast cancer. Eur J Cancer 2000;36:533-4.
62. Menin C, Banna GL, De Salvo G, et al. Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer. Cancer Lett 2001;168:31-6.
63. Colston KW, Hansen CM. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 2002;9:45-59.
64. Friedrich M, Axt-Fliedner R, Villena-Heinsen C, Tilgen W, Schmidt W, Reichrath J. Analysis of vitamin D-receptor (VDR) and retinoid X-receptor a in breast cancer. Histochem J 2002;34:35-40.
65. Guy M, Lowe LC, Bretherton-Watt D, Mansi JL, Colston KW. Approaches to evaluating the association of vitamin D receptor gene polymorphisms with breast cancer risk. Recent Results Cancer Res 2003;164:43-54.